HERMES试验:2次与5次磁共振引导自适应前列腺放疗的随机对照研究
这项单中心、非比较性2期/R-IDEAL 2b试验将46例中危/低高危前列腺癌患者随机分配至5次36.25 Gy或2次24 Gy(大体肿瘤区加量至27 Gy)方案,均采用磁共振直线加速器每日自适应再计划。2次组急性≥2级泌尿生殖毒性为27.3%(6/22),5次组为29.2%(7/24),无3级泌尿生殖毒性;2次组无≥2级胃肠道急性毒性,5次组为6.8%(3/24)。
要点
- 2次SBRT的急性≥2级泌尿生殖毒性为27.3%,与5次方案的29.2%相近。
- 2次SBRT未观察到≥2级胃肠道急性毒性,5次方案为6.8%。
- 12周时2次组尿失禁评分中位数85.5低于5次组的100。
核心结论
- 2次磁共振引导自适应前列腺SBRT的急性泌尿生殖毒性可接受,急性胃肠道毒性低。
- 需随机试验进一步探索晚期毒性和生化控制。
研究设计与样本
- 单中心、非比较性2期/R-IDEAL 2b试验,随机分配46例中危/低高危且多参数MRI可见大体肿瘤区的前列腺癌患者。
- 2次组接受24 Gy分2次(大体肿瘤区加量至27 Gy)共8天,5次组接受36.25 Gy分5次共10天,均使用磁共振直线加速器每日自适应再计划。
- 主要终点为急性≥2级泌尿生殖毒性(CTCAE v5.0)。
主要发现
- 2次组急性≥2级泌尿生殖毒性6/22(27.3%;95% CI,0.11-0.50),5次组7/24(29.2%;95% CI,0.13-0.50),均无3级泌尿生殖毒性。
- 2次组≥2级尿频从第2周4.5%(1/22)升至第4周13.6%(3/22);5次组第2周达16.7%(4/24),第4周降至12.5%(3/24)。
- 12周时EPIC-26尿失禁评分中位数2次组85.5(IQR,75-100),5次组100(IQR,93.8-100);刺激性-梗阻性评分2次组93.8(IQR,87.5-100)高于5次组87.5(IQR,81.3-93.8)。
- IPSS峰值2次组8(IQR,4-11)低于5次组13.5(IQR,10-17)。
- ≥2级胃肠道急性毒性5次组3/24(6.8%),2次组0例。
临床怎么用
- 2次磁共振引导自适应SBRT可作为前列腺癌急性泌尿生殖毒性可接受的超短疗程方案参考。
局限性
- 单中心、非比较性设计,样本量46例。
- 随访限于急性毒性,未报告晚期毒性和生化控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To demonstrate the safety and feasibility of 2-fraction stereotactic body radiation therapy (SBRT) for prostate cancer. METHODS AND MATERIALS: This single-center, noncomparative, phase 2/R-IDEAL 2b trial randomized 46 patients with intermediate/lower high-risk prostate cancer with visible gross tumor volume on multiparametric magnetic resonance imaging to receive 36.25 Gy in 5 fractions over 10 days or 24 Gy in 2 fractions with a gross tumor volume boost up to 27 Gy over 8 days. All treatment was delivered on a magnetic resonance linac with daily adaptive replanning. The primary endpoint was acute grade ≥2 (G2+) genitourinary (GU) toxicity (Common Terminology Criteria for Adverse Events version 5.0). Secondary endpoints include gastrointestinal (GI) toxicity and patient-reported outcomes. RESULTS: G2+ GU acute toxicity was observed in 6 of 22 patients (27.3%; 95% CI, 0.11-0.50) in the 2-fraction group and 7 of 24 patients (29.2%; 95% CI, 0.13-0.50) in the 5-fraction group. There were no grade 3 GU toxicities. G2+ urinary frequency rose from 4.5% (1 of 22) at week 2 to 13.6% (3 of 22) at week 4 in 2-fraction SBRT. G2+ urinary frequency peaked earlier in 5-fraction SBRT at 16.7% (4 of 24) in week 2, falling to 12.5% (3 of 24) at week 4. At 12 weeks, median Expanded Prostate Cancer Index Composite-26 urinary incontinence score was 85.5 (IQR, 75-100) for 2-fraction SBRT and 100 (IQR, 93.8-100) for 5-fraction SBRT. Urinary irritative-obstructive scores were higher at 12 weeks in the 2-fraction group (93.8; IQR, 87.5-100) than in the 5-fraction group (87.5; IQR, 81.3-93.8). Peak International Prostate Symptoms Score was lower in the 2-fraction group (8; IQR, 4-11) than in the 5-fraction group (13.5; IQR, 10-17). G2+ GI acute toxicity occurred in 3 of 24 (6.8%) after 5-fraction SBRT, but none after 2-fraction SBRT. CONCLUSIONS: Acceptable acute GU toxicity was seen after 2-fraction SBRT. Acute GI toxicity was low. Randomized trials are warranted to explore late toxicity and biochemical control.
引用
- Cooper S, Westley RL, Biscombe K, et al. HERMES: Randomized Trial of 2-Fraction or 5-Fraction Magnetic Resonance Imaging-Guided Adaptive Prostate Radiation Therapy. Int J Radiat Oncol Biol Phys. 2025. PMID: 40403882. doi:10.1016/j.ijrobp.2025.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。